According to Marwan Akar, MSD Director General in Russia, Kazakhstan and Belarus, the company is exploring the possibility of localizing in Russia the manufacturing of vaccines to prevent rotavirus and human papillomavirus (HPV) infections, but a positive decision will depend on what infections will be included in the expanded National Vaccination Schedule. Nacimbio, a part of Rostec Corporation, could become one of the partners of MSD.
“We are assessing the capabilities of various Russian partners,” said Marwan Akar.
National Immunobiological Company (Nacimbio) is negotiating with MSD, an American company, on localizing a vaccine against rotavirus infection, said Anton Katlinsky, the President of FORT LLC, a part of Nacimbio holding company, in an interview with Vademecum.
Mr. Katlinsky believes that the MSD vaccine against rotavirus infection will be localized in the next year or two. He did not specify the amount of total investments in the project, but noted that it may be in the “hundreds of millions of rubles.”
In November of 2017, Nacimbio announced that it would invest additional 2.2 billion rubles to expand the range of vaccines manufactured at its FORT plant.
According to the data from the State Register of Medicinal Products, the vaccines against rotavirus infection available currently in Russia are manufactured exclusively by MSD. In particular, this includes RotaTeq, a live pentavalent vaccine.